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Background: Hereditary hemorrhagic telangiectasia (HHT), a rare autosomal dominant disease, is considered
under-diagnosed. Our primary objective was to provide evidence of under-diagnosis of HHT in a North American
population. We hypothesized that variation would exist in the diagnosed prevalence (D-prevalence) across regions
in the province of Ontario, Canada and across age groups, due to under-diagnosis in certain groups. Our secondary
objective was to collect data regarding contact and local access to consult specialists by HHT patients to help guide
potential future diagnostic programs.
Methods: Primary objective- 556 adult patients with a definite HHT diagnosis seen at the Toronto HHT Centre were
identified and geocoded with postal codes. Prevalence rates were calculated using Canadian census data.
Secondary objective- A driving network model was developed in ArcGIS. Service area buffers around ear, nose and
throat (ENT) clinics in Ontario were generated to evaluate the proportion of the Ontario population with access to
these clinics. A survey was also sent to the email contact list of HHT Foundation International, targeting people
with diagnosed HHT, regarding consultation with ENT physicians for epistaxis and timing of HHT diagnosis.
Results: Primary objective- D-prevalence rates varied among regions, from no cases to 1.1 cases per 5000 in large
Ontario cities. There were no significant differences between urban and rural prevalence rates. Variation in
prevalence was seen across age groups, with greater prevalence in older adults (≥50 years-old) compared with
adults 20–49 years-old (0.36 versus 0.26 per 5000, p < 0.0005). Secondary objective- Most Ontarians had access to ENT
clinics within a 30, 60 and 90 minute modeled drive time (92.7%, 97.8% and 98.6%, respectively). Nearly 40%
of surveyed patients consulted an ENT physician for their epistaxis, on average 13.9 ± 12.2 years prior to being
diagnosed with HHT.
Conclusions: The prevalence of HHT in Ontario is highly variable across regions and age-groups, suggesting
under-diagnosis. Given that patients with HHT frequently consult ENT physicians for epistaxis prior to HHT diagnosis,
and that there is almost universal access to ENTs in Ontario, we propose targeting ENT clinics as a province-wide
approach to detect undiagnosed HHT patients and families.
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Hereditary hemorrhagic telangiectasia (HHT) is an auto-
somal dominant disorder of vascular dysplasia. It is char-
acterized by organ arteriovenous malformations (AVMs)
of mainly the lungs, central nervous system and liver, as
well as telangiectases of the dermis and mucous mem-
branes (Figure 1) [1-3]. Both AVMs and telangiectases
are prone to bleeding leading to chronic epistaxis, the
most common symptom of HHT, as well as chronic
gastrointestinal bleeding and life-threatening pulmonary
or cerebral hemorrhage in some patients. AVMs and
telangiectases consist of direct artery-to-vein connections,
and therefore also put patients at risk of life-threatening
complications due to shunting, such as stroke, brain
abscess and high-output cardiac failure [1,3-7].
The diagnosis of HHT in a family is based first on the
clinical diagnosis of HHT of an index case using the
Curaçao Criteria. Once the index case is diagnosed, the
next step is to identify the disease causing HHT muta-
tion in that patient. First-degree relatives can be diag-
nosed using clinical criteria if symptomatic, or by testing
for the familial mutation if asymptomatic or paucisymp-
tomatic [1,3]. The two common genes implicated in
HHT are the endoglin gene (ENG or HHT1) and the
activin A receptor type II-like 1 gene (ALK-1 or HHT2),
both encoding endothelial cell surface proteins of the
TGF-β/BMP-9 signaling pathway [8-10]. A third gene,
SMAD4, has been recently discovered in a small subset
of patients with HHT, primarily in those with an overlap
syndrome with juvenile polyposis [11]. Overall, a disease-
causing mutation can be identified in approximately 80%
of HHT patients, but almost every family has a private
mutation [12,13].
HHT has a broad geographic distribution and is found
widely in many ethnic and racial groups, with an esti-
mated prevalence of at least 1 in 10,000 [1,2,14-19]. ToFigure 1 Clinical manifestations of HHT, including pulmonary arteriov
(right). According to the Curaçao criteria, a confirmed clinical diagnosis of
visceral AVMs, and a positive family history of HHT. Recurrent epistaxis is th
of adults ≥50 years of age. HHT may also be diagnosed genetically based odate, there have been no North American epidemiologic
studies reporting HHT prevalence outside of an estimate
by our group using administrative billing data [20]. As is
the case for many rare diseases, expert opinion is that
HHT is under-diagnosed, though this has not been stud-
ied in North America. This expert opinion, however, is
based on the ongoing HHT Centre experience of regu-
larly identifying new adults and families with HHT.
There is also preliminary evidence in the literature sug-
gesting that HHT is indeed under-diagnosed in Europe
[21], and that diagnosis is often delayed and made only
after serious complications of the disease arise [22].
Given the hereditary nature of HHT, as well as the
very high penetrance of the disease, there should theor-
etically be little-to-no variability in the true prevalence
of the disease across various age groups. However, given
its likely under-recognition and age-related expression,
we expect there to be variability in the actual diagnosed
prevalence of HHT, as suggested in a recently reported
study of HHT diagnoses [20]. Thus, our primary object-
ive was to provide evidence of under-diagnosis of HHT
in North America by estimating the prevalence of the
disease in Ontario, Canada using our provincial HHT
Centre database and population statistics. We hypothe-
sized that there would be variation in the diagnosed
prevalence (D-prevalence) across regions in the province
and across age groups due to under-diagnosis in certain
populations. By demonstrating this, we could then begin
to study approaches to resolving under-recognition of
HHT in North America.
Our secondary objective was to collect data regarding
specialist consultation amongst HHT patients, and model
access to appropriate specialists in order to help guide
potential future diagnostic programs. Given that recurrent
epistaxis is almost universal among adults with HHT, we
surveyed HHT Foundation International contacts aboutenous malformations (left) and mucocutaneous telangiectases
HHT requires 3 or more of epistaxis, mucocutaneous telangiectasia,
e most common symptom of HHT and is present in more than 90 %
n known disease-causing mutations.
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nose and throat (ENT) physicians, for epistaxis, prior to
their diagnosis of HHT. In addition, we estimated geo-
graphic access to ENT physicians across Ontario by devel-
oping a driving network model of the Ontario population’s
access to ENT physicians.
It is our hope that this approach of detecting under-
diagnosis and developing targeted strategies to improve
diagnostic rates may serve as a potential model for other
rare diseases.
Methods
D-prevalence of HHT in Ontario, Canada
The Toronto HHT Centre is a specialized HHT Centre of
Excellence (the only one in Ontario, Canada) that provides
expert multidisciplinary care to HHT patients and families
with suspected or confirmed HHT. The Toronto HHT
Database is a FileMaker Pro relational database, which in-
cludes all of those patients assessed at the Toronto HHT
Centre from 1997 onwards. A comprehensive history and
physical examination was completed by an HHT specialist
for all patients, as well as routine screening for pulmonary
and cerebral AVMs. Genetic testing was recommended to
all families, which most did pursue, in order to identify a
potential familial HHT mutation. Consent was obtained
from all patients to include their clinical information in
the Toronto HHT database.
All adult patients with a definite clinical or genetic
diagnosis of HHT from the Toronto HHT Centre were
identified (N = 627). Postal codes were then recorded for
all but 36 patients (35 deceased, 1 missing address). The
remaining 591 patients were geocoded using their postal
codes, with 35 being excluded (28 patients lived outside
of Ontario, 7 patients could not be geocoded). In total,
556 (98.5%) patients living in Ontario were successfully
geocoded. The population of Ontario was determined
using 2006 Canadian census data and was used to calcu-
late the D-prevalence of HHT in the province.
In order to identify any potential causes for under-
diagnosis, the D-prevalence of HHT in urban settings
was compared to that of rural areas in Ontario. All census
subdivisions (CSDs) with a population of ≥1000 within
Ontario Census Metropolitan Areas (CMAs), as defined
by Statistics Canada, were identified (n = 125) and used
to represent the urban study area. The remaining CSDs
in Ontario represented the rural study area. For each
urban CSD and for the rural portion of Ontario, HHT
patient counts were calculated for 2 age groups (20-49
and ≥50 years-old) and the D-prevalence of HHT within
each age group was then calculated using aged-match
total population counts from the 2006 Census of
Canada. The ≥20 years-old cut-off was used since the
Canadian Census reports age-related population data by
decade only, and did not include isolated populationdata on adults less than 20 years old. The ≥50 years-old
cut-off was chosen since previous studies have shown
that at least 90% of patients with HHT are symptomatic
by this age [4].
In order to eliminate overestimation biases due to large
families living in small cities, D-prevalence rates were also
compared specifically between large Ontario cities, de-
fined as those cities with a population ≥50,000, and very
large cities, defined as cities with a population ≥250,000.Specialist consultation by patients with HHT
A web-based survey targeting physician-diagnosed HHT
patients was distributed to all HHT Foundation Inter-
national email contacts (N = 2836). Demographic informa-
tion including sex, present age, and age at time of HHT
diagnosis were obtained. Participants with a self-reported
but physician-determined diagnosis of HHT were asked
about the presence of recurrent epistaxis. In those report-
ing epistaxis, further survey questions enquired about
specialist consultation with ENT and ER physicians prior
to their HHT diagnosis.Access to ENT clinics across Ontario
A driving network model for all roads in Ontario was
developed in ArcGIS, a geographic information system
used to create maps, and compile and analyze geo-
graphic data. An estimated drive time for each road
segment was estimated using non-rush hour speed
limits, road length, and elevation change. Direction of
travel restrictions were implemented for one-way
streets and divided highways. The model also included
impedances for travel delay at intersections, ranging
from 5 to 30 seconds depending on the direction of
travel (i.e. left or right turn, proceed straight) and the
type of road (i.e. primary, secondary, local).
Using postal codes retrieved from the Ontario Medical
Association as well as the College of Physicians and
Surgeons of Ontario websites, locations of ENT clinics
were geocoded. Service area buffers were then generated
around each clinic to model the area which could be
traveled to within a 30, 60 and 90 minute drive in any
direction from the clinic location. Service area buffers
were then combined for each time category to create
three large buffers of the entire area in Ontario in which
residents could access an ENT clinic within a 30, 60 or
90 minute drive.
Identifiers were then assigned to 2006 census dissem-
ination areas (DAs) based on whether their geometric
center point (i.e. centroid) was located within the buffer
for a given time. Total populations were assigned to each
DA based on the 2006 Census of Canada. The total
number of Ontarians within a 30, 60 and 90 minute
drive of an ENT clinic was then determined.
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GraphPad Prism, a commercial scientific 2D graphing
and statistical software, was used to generate all graphs
and statistical analysis. Chi-square test was used to
calculate statically significant differences in D-prevalence
rates of HHT across cities, in urban versus rural centers,
as well as differences in D-prevalence between various
age groups across Ontario.
Ethics
Ethics approval for this study was obtained from the St.
Michael’s Hospital Research Ethics Board in Toronto,
Ontario, Canada. Previous informed consent was given by
all patients included in our Toronto HHT Centre database.
Results
Variability of D-prevalence across all cities in Ontario
In total, there were 556 adult (≥20 years old) patients in
the Toronto HHT Database with a confirmed diagnosis
of HHT and living in the province of Ontario. There
were 9,116,380 adults (≥20 years) living in Ontario in
2006, making the D-prevalence of HHT approximately
0.31 per 5000 people. The D-prevalence varied signifi-
cantly across all regions of Ontario from no cases in 59
cities to as high as 9.4 cases per 5000 people in one
smaller city (Figure 2). There were no significant differ-
ences between overall urban and rural D-prevalence
rates (0.31 versus 0.30 per 5000, p = 0.79).
Variability of D-prevalence in large cities in Ontario
Of the 34 large cities (population ≥50,000 adults) in On-
tario, there was no correlation (R2 = 0.0005) between the
population size and the D-prevalence, which ranged
from no cases to 1.1 cases per 5000 adults (Figure 3).
Variability in D-prevalence across age groups
Of the 556 adults with confirmed HHT, 275 were 20-49
years-old and 281 were ≥50 years-old. D-prevalence rates
were significantly higher in older adults compared to
younger adults (0.36 versus 0.26 per 5000, respectively,
p < 0.0005) (Figure 4). This difference held true even for
the very large Ontario cities (population ≥250,000 adults),
where the overall D-prevalence was 0.28 per 5000. In
these cities, the D-prevalence was 0.22 versus 0.38 per
5000 for the 20-49 and ≥50 years-old age groups, respect-
ively (p < 0.00005) (Table 1). Very similar results were
found for large Ontario cities (population ≥50,000 adults).
Survey of HHT foundation international HHT patients
940 participants with a self-reported physician-confirmed
diagnosis of HHT completed the web-based survey, 79%
of whom were North American. A large majority of parti-
cipants (86%) reported a history of recurrent epistaxis and
nearly 40% had consulted an ENT physician for epistaxisprior to being diagnosed with HHT. The mean reported
time between this initial consult and HHT diagnosis was
13.9 ± 12.2 years (Table 2).
Access to ENT clinics in Ontario
The vast majority of the adult Ontario population had
access to an ENT clinic within a 30, 60 and 90 minute
drive (92.7%, 97.8% and 98.6%, respectively) (Figure 5).
Discussion
In this study, we have provided data supporting the
under-diagnosis of HHT in Ontario. We have also
shown almost universal access to ENT clinics for the
Ontario population and evidence that HHT patients are
consulting ENT physicians for epistaxis, both of which
support an approach targeting ENT physicians in im-
proving the diagnostic rates of HHT. For many patients,
there is a substantial delay between their initial ENT
consult and receiving a diagnosis of HHT. This lapse
represents a significant opportunity to intervene and
reduce both the morbidity and mortality associated with
HHT.
We have demonstrated a D-prevalence of HHT in
Ontario of approximately 0.31 per 5000 individuals.
However, there is also good evidence supporting under-
diagnosis in the province. The D-prevalence of HHT
varied widely between cities in Ontario, and could not
be explained by differences in urban versus rural areas.
In order to eliminate overestimation biases due to large
families living in small cities, D-prevalence rates were
compared specifically between cities with a popula-
tion ≥50,000. Even in these larger centers, many of
which had tertiary hospitals and specialized expertise, there
was still significant variation in the D-prevalence across
cities.
Moreover, the D-prevalence of HHT was significantly
greater in older adults compared with younger ones in
the province. Given the genetic nature of the disease, all
patients with HHT are born with the disorder and gen-
etic testing is available for pre-symptomatic diagnosis.
As such, a difference in D-prevalence between age
groups should not be seen unless HHT is being under-
recognized in some age groups. From a clinical perspec-
tive, many of the symptoms of HHT, including recurrent
epistaxis and telangiectasia, become more prevalent with
age and are most consistently present by age 50 years,
making the clinical diagnosis of HHT easier. In contrast,
genetic testing is often necessary for confirmation of the
diagnosis in younger adults and children, many of whom
may be asymptomatic or have only mild symptomatology
but are still at risk for AVM complications [1,4,5,23-27].
This may partially explain the difference in D-prevalence
between the different age groups and the under-diagnosis
of HHT in younger adults.
Figure 2 Variation in D-prevalence across all cities in Ontario, Canada. Each circle represents a given D-prevalence from one or more
Ontario cities. There were 59 cities with no reported cases of HHT. The D-prevalence of HHT varied significantly across included regions and
ranged from no cases to 9.4 per 5000 adults.
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Ontario (0.31 per 5000) and the highest D-prevalence seen
in a large Ontario city (1.1 per 5000) to approximate the
true province-wide prevalence, it is estimated that as
many as 70% of the HHT cases are undiagnosed in
Ontario. This represents an estimated 1400 individuals in
Ontario who are unaware of their diagnosis and are at risk
of life-threatening, but preventable, complications.
Given the nearly universal access to ENT clinics for
Ontarians, we believe that ENT physicians are an excel-
lent target to improve the diagnostic rates of HHT. Recur-
rent epistaxis is the most common symptom of HHT,
occurring in approximately 90% of patients over 50 years-
old [1,4,5]. Recurrent epistaxis is, therefore, a very sensi-
tive clinical biomarker of HHT. Individuals with HHT
often seek the care of ENT specialists or ER physicians in
managing their epistaxis. In our web-based survey, nearly
40% of participants consulted an ENT physician, most as
young adults, prior to being diagnosed with HHT.However, the time between this initial consult and receiving
a diagnosis was a staggering 14 years. This represents a
critical period in which serious complications of HHT can
occur, and a time in which individuals may choose to have
children who are at a 50% risk of inheriting the disease.
While recurrent epistaxis may not be a very specific clin-
ical biomarker, since it is a symptom shared by many dis-
eases, it is highly sensitive and would capture the majority
of patients with undiagnosed HHT. This may prove useful
in any campaign focused on improving diagnostic rates and
reducing disease-related mortality and morbidity. To ac-
complish this, further work, in conjunction with ENT
specialists, will be required to determine effective, effi-
cient and feasible methods of delineating HHT-related
epistaxis from non-HHT-related epistaxis.
It is important to acknowledge the limitations of this
study. As the only HHT Centre for adults in Ontario, we
assumed that the Toronto HHT Centre manages the
majority of patients with known HHT in the province.
Figure 3 City size versus D-prevalence in large cities in Ontario, Canada. In order to eliminate overestimation biases due to large families
with HHT living in small cities, the D-prevalence of HHT was compared in large cities, defined as those centers with a population ≥50,000. Even
amongst these cities, there was still significant variation in the D-prevalence across regions, which ranged from no cases to 1.1 cases per 5000
adults. There was no correlation between the population size and the D-prevalence (R2 = 0.0005).
Figure 4 Variation in D-prevalence across age-groups in all cities in Ontario, Canada. D-prevalence rates were significantly higher in older
adults (0.36 ± 0.32 per 5000) compared to younger adults (0.26 ± 0.22 per 5000).
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Table 1 Variation in D-prevalence across age groups in very large cities in Ontario, Canada
City Population size Total number of confirmed
HHT cases
D-prevalence for 20–49 year-olds
(per 5000)
D-prevalence for ≥50 year-olds
(per 5000)
London 267,145 14 0.22 0.31
Brampton 303,700 16 0.20 0.40
Hamilton 379,780 26 0.24 0.48
Mississauga 486,270 16 0.16 0.17
Ottawa 614,770 20 0.16 0.16
Toronto 1,947,455 134 0.25 0.48
Total 3,999,120 226 0.22* 0.38*
Note: the combined adult population of these cities comprises 50 % of the entire adult population of Ontario; *denotes a statistically significant difference
of p < 0.00005.
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institution, with variation in D-prevalence across cities
being somewhat due to referral patterns. For instance,
some academic centres outside of Toronto may be
undertaking management of patients with the disease,
which may partly explain the lower D-prevalence rates
from certain major Ontario cities like Ottawa. However,
these postulated differences in referral patterns are likely
to impact patient capture from all ages and cannot ex-
plain the variation in D-prevalence seen amongst differ-
ent age groups, suggesting that under-diagnosis is a true
concern. Moreover, it is plausible that differences seen
in D-prevalence between Ontario cities may be partly
accounted for by settlement patterns and the Founder
effect, as reported in previous HHT studies [28,29]. We
accounted for this by comparing the D-prevalence of
HHT between large cities in an attempt to reduce over-
estimation bias both when calculating D-prevalence and
estimating the percentage of undiagnosed HHT cases.
The variation in D-prevalence seen across large cities
and across age groups cannot be accounted for by settle-
ment patterns alone and is once again suggestive of
under-diagnosis. However, it is important to acknowledgeTable 2 Survey of HHT patients regarding consultation for ep
timing of HHT diagnosis
Proportion of respondents (%)
Mean age ± SD at time of survey
Mean age ± SD at time of diagnosis
Proportion of females (%)
Proportion of North Americans
Proportion of patients with recurrent epistaxis (%)
Proportion of patients with ENT consult prior to HHT diagnosis (%)
Proportion of patients with ER consult prior to HHT diagnosis (%)
Mean age ± SD at first ENT consult
Mean age ± SD at first ER consult
Mean interval of time ± SD from initial ENT consult to HHT diagnosis
Mean interval of time ± SD from initial ER consult to HHT diagnosisthat while upwards of 70% of HHT cases may be undiag-
nosed in Ontario, this estimate captures both unidentified
HHT cases as well as patients with suspected disease in
which a definite diagnosis has been difficult to make. Al-
though this may account for some of the differences in D-
prevalence, especially between age groups, it is likely to be
of minimal impact given that the majority of our patients
with suspected HHT are negative for a known disease-
causing mutation. Next, the web-based survey used is
limited by both response bias, since individuals without
access to a computer or email were excluded, and recall
bias. Driving times were calculated under minimal to no
traffic conditions, which is an unlikely occurrence. Regard-
less, even with the addition of a 30 to 60 minute traffic
delay, nearly 93% of Ontarians are within a 60 to 90 minute
drive of an ENT clinic. Finally, access to ENT clinics was
calculated under the assumption that all Ontarians drive or
own a motor vehicle, and the reported access rates are thus
likely to be a slight overestimate.
The Rare Diseases Act of 2002 defines a rare disease as
one that affects less than 200,000 people in the United
States, with more than 6000 diseases meeting this crite-
rion [30]. According to the National Organization for Rareistaxis with ENT specialists and ER physicians and relative
940/2836 (33 %)
54.1 ± 14.1 years






27.8 ± 16.8 years
30.1 ± 17.4 years
13.9 ± 12.2 years
11.3 ± 12.6 years
Figure 5 Access to ENT clinics in Ontario, Canada. The vast majority of adult Ontarians have access to an ENT clinic within a 30, 60 and
90 minute modeled drive time (92.7 %, 97.8 % and 98.6 %, respectively. While the majority of Northern Ontario appears outside the access zones
(grey), only a very small proportion (<10 %) of the population inhabits this region of the province.
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a rare disease, an astounding rate that is comparable to
major illnesses like diabetes mellitus. Patients with rare
diseases often receive multiple and incorrect diagnoses for
years before ever receiving the correct one [14,22,31,32].
In this time, serious complications associated with the dis-
ease may occur, which is our concern with respect to
HHT. By implementing strategies to improve the recogni-
tion and diagnoses of HHT, we may be able to intervene
and help guide patients to the resources and specialized
management that they require. This may also lead to
subsequent diagnoses in several other family members,
especially in autosomal dominant disorders like HHT. We
speculate that these same approaches might be relevant
for other hereditary rare diseases as well.
In this article, we have presented a novel approach
that we hope will help to improve the diagnostic rates of
HHT and serve as an example for other rare diseases.
This innovative model consists of: 1) providing evidence
of under-diagnosis; 2) identifying a sensitive clinical bio-
marker (e.g. recurrent epistaxis) in the disease; 3) target-
ing specialists that are consulted for this biomarker; 4)
ensuring patients have access to these specialists; and 5)
developing disease awareness programs and diagnostic
initiative strategies to improve the recognition and diag-
noses of a given rare disease. By detecting index cases,
both symptomatic and asymptomatic family members
may then be screened through clinical and geneticevaluation. Those affected by the disease may undergo
subsequent screening and potentially preventative ther-
apies, when available.Conclusion
By identifying variation in the D-prevalence of HHT
across different cities and age groups in Ontario, we
have provided evidence of the under-diagnosis of HHT
in North America. Given that recurrent epistaxis is very
common in HHT, it is a sensitive clinical biomarker in
the disease. By exploiting this and collecting data regard-
ing specialist consultation amongst HHT patients and
population access to these specialists, we have identified
ENT physicians as an excellent target group to involve
for improving the diagnostic rates of HHT. The implica-
tion is that a province-wide detection program involving
ENT physicians is feasible, with the goal of detecting
index cases of HHT and unrecognized HHT families.
While this study focused specifically on HHT, we believe
that the strategies used here can be more generally
employed as a model approach for identifying and im-
proving under-diagnosis in other rare diseases.Abbreviations
AVM: Arteriovenous malformation; CSD: Census subdivision; CMA: Census
metropolitan area; DA: Dissemination areas; D-prevalence: Diagnosed
prevalence; ENT: Ears, nose and throat; ER: Emergency room; HHT: Hereditary
hemorrhagic telangiectasia; NORD: National organization for rare disorders.
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